Tejnaksh Healthcare Ltd
Incorporated in 2008, Tejnaksh Healthcare
Ltd is in the business of Healthcare Services
and Pharmacies[1]
- Market Cap ₹ 51.3 Cr.
- Current Price ₹ 25.2
- High / Low ₹ 34.9 / 21.2
- Stock P/E 22.3
- Book Value ₹ 11.8
- Dividend Yield 0.00 %
- ROCE 11.4 %
- ROE 8.28 %
- Face Value ₹ 5.00
Pros
- Company has reduced debt.
- Debtor days have improved from 35.0 to 20.0 days.
- Company's working capital requirements have reduced from 18.1 days to 10.7 days
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of -10.0% over past five years.
- Company has a low return on equity of 9.50% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Healthcare
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1.14 | 1.44 | 2.01 | 4.75 | 6.53 | 8.62 | 13.96 | 11.50 | 8.56 | 8.12 | 7.34 | 8.22 | 8.40 | |
0.55 | 0.49 | 1.04 | 2.45 | 3.67 | 4.37 | 10.34 | 7.93 | 4.96 | 3.76 | 4.21 | 4.57 | 4.28 | |
Operating Profit | 0.59 | 0.95 | 0.97 | 2.30 | 2.86 | 4.25 | 3.62 | 3.57 | 3.60 | 4.36 | 3.13 | 3.65 | 4.12 |
OPM % | 51.75% | 65.97% | 48.26% | 48.42% | 43.80% | 49.30% | 25.93% | 31.04% | 42.06% | 53.69% | 42.64% | 44.40% | 49.05% |
0.00 | 0.01 | 0.04 | 0.03 | 0.20 | 0.43 | 1.42 | 0.48 | 0.14 | 0.08 | 0.24 | 0.28 | 0.28 | |
Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.19 | 0.96 | 0.77 | 0.80 | 0.54 | 0.48 | 0.62 | 0.70 | 0.58 |
Depreciation | 0.11 | 0.11 | 0.14 | 0.21 | 0.34 | 0.44 | 0.52 | 0.59 | 0.61 | 0.59 | 0.79 | 0.80 | 0.87 |
Profit before tax | 0.48 | 0.85 | 0.87 | 2.12 | 2.53 | 3.28 | 3.75 | 2.66 | 2.59 | 3.37 | 1.96 | 2.43 | 2.95 |
Tax % | 35.42% | 32.94% | 32.18% | 37.74% | 33.20% | 26.22% | 28.27% | 27.44% | 22.39% | 25.22% | 30.10% | 25.51% | |
0.31 | 0.57 | 0.60 | 1.32 | 1.69 | 2.43 | 2.69 | 1.92 | 2.00 | 2.52 | 1.38 | 1.81 | 2.30 | |
EPS in Rs | 0.41 | 0.65 | 0.84 | 1.20 | 1.33 | 0.95 | 0.99 | 1.24 | 0.68 | 0.89 | 1.14 | ||
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | 19% |
5 Years: | -10% |
3 Years: | -1% |
TTM: | 15% |
Compounded Profit Growth | |
---|---|
10 Years: | 12% |
5 Years: | -8% |
3 Years: | -3% |
TTM: | 158% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | -3% |
3 Years: | -25% |
1 Year: | -12% |
Return on Equity | |
---|---|
10 Years: | 15% |
5 Years: | 11% |
3 Years: | 10% |
Last Year: | 8% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 0.01 | 0.01 | 0.80 | 1.10 | 2.21 | 2.21 | 10.16 | 10.16 | 10.16 | 10.16 | 10.16 | 10.16 | 10.16 |
Reserves | 1.31 | 1.88 | 1.69 | 5.14 | 5.73 | 8.19 | 2.93 | 4.85 | 6.87 | 9.40 | 10.79 | 12.62 | 13.78 |
0.36 | 0.47 | 0.00 | 0.00 | 6.39 | 7.64 | 6.33 | 7.25 | 4.93 | 7.03 | 6.45 | 4.79 | 2.87 | |
0.33 | 0.62 | 1.04 | 0.60 | 0.55 | 1.13 | 1.99 | 2.02 | 1.92 | 2.09 | 2.40 | 2.55 | 3.18 | |
Total Liabilities | 2.01 | 2.98 | 3.53 | 6.84 | 14.88 | 19.17 | 21.41 | 24.28 | 23.88 | 28.68 | 29.80 | 30.12 | 29.99 |
1.37 | 1.43 | 2.86 | 3.34 | 13.43 | 14.54 | 16.19 | 16.59 | 14.34 | 14.55 | 22.51 | 22.14 | 22.94 | |
CWIP | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.39 | 0.65 | 0.79 | 8.89 | 0.95 | 1.07 | 0.00 |
Investments | 0.00 | 0.00 | 0.01 | 2.59 | 0.07 | 1.06 | 1.06 | 1.06 | 1.06 | 1.06 | 1.06 | 1.06 | 1.06 |
0.64 | 1.55 | 0.65 | 0.91 | 1.38 | 3.57 | 3.77 | 5.98 | 7.69 | 4.18 | 5.28 | 5.85 | 5.99 | |
Total Assets | 2.01 | 2.98 | 3.53 | 6.84 | 14.88 | 19.17 | 21.41 | 24.28 | 23.88 | 28.68 | 29.80 | 30.12 | 29.99 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0.11 | 0.08 | 1.71 | 3.67 | 1.78 | 3.88 | 3.15 | 1.00 | 0.84 | 9.13 | 1.90 | 4.15 | |
-0.08 | -0.17 | -1.59 | -3.26 | -7.91 | -2.59 | -1.49 | -1.16 | 1.56 | -10.40 | -0.98 | -1.08 | |
-0.01 | 0.11 | -0.04 | -0.13 | 6.39 | -0.64 | -2.08 | 0.22 | -2.86 | 1.61 | -1.17 | -2.31 | |
Net Cash Flow | 0.02 | 0.02 | 0.08 | 0.29 | 0.26 | 0.64 | -0.42 | 0.06 | -0.47 | 0.35 | -0.25 | 0.75 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.75 | 16.82 | 15.78 | 20.23 | 64.65 | 19.98 |
Inventory Days | 98.06 | 86.45 | 126.74 | 182.50 | 340.67 | 251.90 | 142.64 | 236.18 | ||||
Days Payable | 114.40 | 134.47 | 177.43 | 143.79 | 129.78 | 77.11 | 117.47 | 75.15 | ||||
Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | -16.34 | -48.03 | -50.69 | 5.75 | 55.53 | 226.67 | 195.02 | 89.82 | 181.01 |
Working Capital Days | 102.46 | 240.80 | -5.45 | -1.54 | 19.56 | -5.93 | 24.58 | 105.37 | 9.81 | -13.93 | 57.68 | 10.66 |
ROCE % | 31.37% | 42.08% | 36.29% | 48.57% | 26.45% | 26.20% | 24.13% | 16.60% | 14.20% | 16.07% | 9.56% | 11.39% |
Documents
Announcements
-
Closure of Trading Window
16 Dec - Closure of trading window for securities.
-
Announcement Of Indian Patent Grant For Pflow - A Milestone Achievement By Dr. Ashish Rawandale Patil
16 Dec - Indian patent granted for Pflow, enhancing kidney healthcare.
- Submission Of Un-Audited Financial Results (Standalone & Consolidated) For The Quarter Ended On 30Th September 2024. 14 Nov
-
Board Meeting Outcome for Outcome Of Board Meeting In Accordance With SEBI (Listing Obligations And
Disclosure Requirements) Regulations, 2015
14 Nov - Approved un-audited financial results for Q2 FY2024.
-
Board Meeting Intimation for Regulation 29 Of SEBI (LODR) Regulations, 2015 And Closure
Of Trading Window
7 Nov - Board meeting to approve financial results on Nov 14, 2024.
Annual reports
Concalls
-
Feb 2018TranscriptNotesPPT
Business Overview:[1][2]
THL provides hospital and healthcare service in Mumbai and other parts of Maharashtra. It has ~13 urology clinics, ~4 urology hospitals and ~2 dental super speciality clinics. Company also runs a teaching institute recognized by the Ministry of Health and Family welfare. It has more than 150 research papers, 23 innovations, 13 patents applied.